Ascendis Pharma Stock Price, News & Analysis

Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021. Company executives will present a business overview and update on its pipeline programs. The event will be held virtually at 4:15 p.m. Eastern Time. A live audio webcast will be accessible on the Company’s website and will be available for replay for 30 days post-event. Ascendis Pharma focuses on utilizing its TransCon technologies to develop therapies for unmet medical needs, currently featuring a pipeline in endocrinology and oncology.

Ascendis Pharma A/S (Nasdaq: ASND) has announced presentations featuring TransCon hGH (lonapegsomatropin) at two medical conferences: Pediatric Endocrinology Nursing Society (PENS) from April 21-23 and Pediatric Endocrine Society (PES) from April 30-May 3, 2021. The company will present two-year follow-up data on the efficacy and safety of lonapegsomatropin in children with growth hormone deficiency (GHD), alongside a model for estimating average IGF-1 levels. The presentations aim to support healthcare providers in managing patients post-regulatory approval.

Ascendis Pharma A/S (Nasdaq: ASND) announced participation in the J.P. Morgan 10th Annual Napa Valley Biotech Forum on March 30, 2021, at 4:00 p.m. ET. The forum will be virtual, allowing company executives to present a business overview and updates on their pipeline programs. The event underscores Ascendis' commitment to expanding its portfolio of rare disease and oncology product candidates using its innovative TransCon technologies. A live audio webcast will be available on the company’s website, with a replay accessible for 30 days post-event.

Ascendis Pharma A/S presented promising data on TransCon PTH at the Endocrine Society's annual meeting, highlighting its potential as a hormone replacement therapy for adults with hypoparathyroidism. In a six-month open-label extension of the Phase 2 PaTH Forward Trial, over 90% of 58 subjects achieved independence from conventional treatments, while maintaining normal serum calcium levels. Notably, patient-reported outcomes improved significantly. TransCon PTH remains well-tolerated without serious adverse events. Upcoming PaTHway Trial phase 3 data is expected in Q4 2021, aiming to further assess safety and efficacy.

Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 11:20 a.m. Eastern Time. The virtual event will feature company executives providing a business overview and updates on its pipeline programs. Ascendis Pharma develops innovative therapies using its TransCon technologies, focusing on endocrinology and oncology. The company continues to expand its product pipeline, which includes three endocrinology rare disease candidates and one oncology candidate in clinical development.

Ascendis Pharma A/S (ASND) announced financial results for 2020, showing a net loss of €419.0 million, or €8.28 per share, compared to €218.0 million in 2019. Revenue decreased to €7.0 million from €13.4 million. R&D expenses rose to €260.9 million, driven by personnel costs and facility expansion. Cash reserves improved to €834.1 million from €598.1 million. Key milestones include preparations for launching TransCon hGH in the U.S. in Q3 2021 and ongoing clinical trials for several product candidates, with important regulatory updates expected in 2021.

Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in ENDO 2021, showcasing seven presentations on its innovative TransCon™ technologies. Key highlights include the first presentation of 6-month data from the phase 2 PaTH Forward trial for adult hypoparathyroidism, demonstrating the potential of TransCon PTH in reducing standard care treatments while maintaining normal serum calcium. Additionally, two-year follow-up data for TransCon hGH (lonapegsomatropin) shows durable results in children with growth hormone deficiency. The presentations will address significant advancements in endocrinology.

Ascendis Pharma A/S (Nasdaq: ASND) will host a conference call on March 10, 2021, at 4:30 p.m. ET to discuss its 2020 financial results and provide a business update. Investors can access the call via dial-in numbers or a live webcast on the company's website. The firm is advancing its TransCon technologies and currently has a pipeline of three endocrinology rare disease candidates and one oncology candidate in clinical development. Ascendis aims to expand into additional therapeutic areas.

Ascendis Pharma A/S (Nasdaq: ASND) has launched Outgrow GHD, an online resource tailored for caregivers of children with growth hormone deficiency (GHD) in the U.S. The initiative aims to improve awareness and support for families navigating challenges associated with GHD. The platform offers educational materials, tools for engagement, and a quiz to discover parenting styles related to GHD.

The resource highlights the need for community support among families affected by rare diseases and will expand to include additional topics relevant to GHD management.